<DOC>
	<DOCNO>NCT02824458</DOCNO>
	<brief_summary>The main purpose study evaluate safety efficacy Apatinib combination Gefitinib compare placebo combination Gefitinib participant stage ⅢB-IV Non-squamous non-small-cell lung cancer ( NSCLC ) harbor activate epidermal growth factor receptor ( EGFR ) mutation ( Del19 L858R ) . Safety tolerability Apatinib combination Gefitinib assess first portion ( Part A ) proceed second portion study ( Part B ) .</brief_summary>
	<brief_title>A Study Gefitinib With Without Apatinib Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>1 . ≥ 18 ≤ 70 year age 2 . Eastern Cooperative Oncology Group ( ECOG ) performance scale 0 1 . 3 . Life expectancy 3 week . 4 . Histologically cytologic confirmed，locally advanced and/or metastatic nonsquamous NSCLC stage IIIB ( unsuitable radiotherapy ) IV recurrent NSCLC ; At least one measurable lesion accord RECIST 1.1 receive radiotherapy cryotherapy . 5 . Documented evidence tumor harbor activate EGFR mutation ( Example 19 del L858R ) . 6 . None previous chemotherapy target therapy . NOTE : neoadjuvant and/or adjuvant therapy allow complete 6 month . 7 . Prior radiation therapy allow : 25 % less total bone marrow irradiate , pelvis chest irradiate ; least 4 week elapse completion radiation treatment , acute toxicity radiation treatment recover ; irradiate lesion include measurable lesion unless documented progress radiation . 8 . Adequate hepatic , renal , heart , hematologic function ( Absolute Neutrophil Count ( ANC ) ≥ 1.5×109/L , Platelet ( PLT ) ≥ 100×109/L , Hemoglobin ( HB ) ≥ 100 g/L , total bilirubin within 1.5×the upper limit normal ( ULN ) , serum transaminase≤2.5×the Upper Limit Of Normal ( ULN ) , serum creatine ≤ 1 x Upper Limit Of Normal ( ULN ) , creatinine clearance rate ≥ 50ml/min , 9 . For woman childbearing age , pregnancy test result ( serum urine ) within 7 day enrolment must negative . They take appropriate method contraception study 8th week post last administration study drug . For men ( previous surgical sterilization accept ) , take appropriate method contraception study 8th week post last administration study drug . 10 . Signed date informed consent . Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure . 1 . Squamous cell carcinoma ( include adenosquamous carcinoma , undifferentiated carcinoma ) ; small cell lung cancer ( include small cell nonsmall cell mixed lung cancer ) 2 . Symptomatic brain metastasis ( Patients symptom need receive therapy 21 day may participate trial , need confirm MRI\CT venography hematencephalon symptom ) ; 3 . Radiologically document evidence major blood vessel invasion encasement cancer ; Obvious cavity necrosis form tumor . 4 . Uncontrolled hypertension ( systolic pressure ≥ 140 mmHg and/or diastolic pressure ≥ 90 mm Hg ) even though two two hypotensive agent application . 5 . Patients suffer grade II myocardial ischemia myocardial infarction , uncontrolled arrhythmia ( include QT interval male ≥ 450 m , female ≥ 470 m ) . Grade IIIIV cardiac insufficiency accord New York Heart Association ( NYHA ) criteria echocardiography check : leave ventricular ejection fraction ( LVEF ) &lt; 50 % ; 6 . History pulmonary interstitial disease concurrent pulmonary interstitial disease . 7 . Coagulation disfunction（INR＞1.5 rPT＞Upper Limit Of Normal ( ULN ) +4s Activated Partial Thromboplastin Time ( APTT ) &gt; 1.5 Upper Limit Of Normal ( ULN ) ） , hemorrhagic tendency receive therapy thrombolysis anticoagulation . 8 . History clinically significant haemoptysis = &lt; 2 month ( 2.5ml half one tea spoon fresh blood per day ) prior registration . 9 . History clinically relevant major bleed event ( e.g . gastrointestinal hemorrhage , bleed gastric ulcer , occult blood test ≥ ( ++ ) , vasculitis ; 10 . Within 6 month first treatment occur artery / venous thromboembolic event , cerebral vascular accident ( include transient ischemic attack ( TIA ) , hematencephalon , cerebral infarction ) , deep vein thrombosis pulmonary embolism , etc . 11 . Known inherited acquire hemorrhagic thromboplastic possibility ( hemophilia , coagulopathy , thrombocytopenia , hypersplenism , etc . ) 12 . Longterm untreated wound fracture . 13 . Within 4 week major surgery and/or injures , fracture , ulceration . 14 . Significant factor influence ingestion absorption medicine , ( e.g . unable swallow , chronic diarrhea intestinal obstruction ) ; 15 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess ≤ 6 month . 16 . Urine protein≥++ , 24h urine protein quantitation≥1.0g ; 17 . Symptomatic serous effusion require treatment . ( include hydrothorax , ascites , hydropericardium ) ; 18 . Active infection need antimicrobial treatment ; 19 . History psychiatric drug abuse abstinent , dysphrenia ; 20 . Less 4 week last clinical trial 21 . History concomitant malignancy except cure basal cell skin cancer , carcinoma situ cervix , superficial bladder cancer ; 22 . Administration strong/potent cytochrome P450 ( CYP ) 3A4 inhibitor within 7 day , inducer within 12 day ; 23 . Pregnant breastfeeding woman ; 24 . Other condition regiment investigator ' discretion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>EGFR tyrosine kinase inhibitor</keyword>
	<keyword>VEGFR inhibitor</keyword>
	<keyword>NSCLC</keyword>
</DOC>